Allows pharmacists to transfer Schedule II attention-deficit/hyperactivity disorder prescriptions.
Impact
This amendment is particularly significant given the increased demand for ADHD medications and the prevalent shortages in availability due to various factors, including pharmacy stock issues. Previously, if a patient could not fill their prescription at their regular pharmacy, they were required to seek a new prescription from their healthcare provider to start the process over. A4391 streamlines this process, tremendously benefiting patients by allowing them to have their prescriptions transferred directly.
Summary
Assembly Bill A4391, introduced in May 2024, seeks to amend existing New Jersey law regarding the transfer of prescriptions specifically for Schedule II controlled dangerous substances intended for individuals with attention-deficit/hyperactivity disorder (ADHD). The bill allows pharmacists to transfer these prescriptions between pharmacies, enhancing the ability for patients to fill their medications more efficiently. By aligning with recent changes in federal regulations, this legislation expands the scope of allowable prescription transfers, which were previously limited to Schedule III-V substances.
Contention
While the bill is designed to alleviate the burdens on patients needing ADHD medications, discussions surrounding it may arise from concerns about adequately regulating the access and transfer of Schedule II substances. Critics might raise points regarding potential misuse or the implications of increased access to these medications. Nonetheless, the overarching intention of the bill is to enhance access to necessary healthcare services for patients with ADHD, which is an important consideration in the current healthcare landscape.
Revises telehealth and telemedicine requirements concerning adult prescription of certain Schedule II drugs for treatment of attention-deficit/hyperactivity disorder.
Authorizes pharmacists to dispense HIV prophylaxis without individual prescription under certain circumstances; mandates prescription benefits coverage.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.